altamira medica

AM-301

Mitigating risk from exposure to airborne viruses and allergens

Auris Medical Business Update / April 13, 2021

Forward-looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Auris Medical's need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Agenda

- Product profile
- Allergy data
- Viral infection data
- Commercialization
- Market potential

Danger in the Air

Every day you breathe in just over 2000 gallons of air…



Nasal mucosa

- Up to 90% of air inhaled via the nose
- Exposure to airborne virus, bacteria, allergen or dirt particles
- Nasal mucosa acts as a protective barrier against these particles
  - Secretes mucus which traps particles
  - Clearance via the throat
- Occasionally overwhelmed or breaks down
  - Nasal dryness or irritation
  - Mucosal damage
- Allergic reactions (hay fever, dust mite allergies…)
- Viral infections (influenza, common cold, SARS, MERS…)

How AM-301 Acts

Complements the natural defense of the nasal mucosa

Triple protective effect aids in the defense against airborne particles

Protects
as a physical barrier
the nasal mucosa

Traps
airborne particles through
electrostatic effects

Humidifies
the nasal mucosa and
thus aids its functionality



- Protective barrier
- Nasal mucosa
- Binding of virus & allergen particles
- Humidification of nasal mucosa

Key Features of AM-301

A nasal spray for convenient self-protection

Trap to remove
Capturing particles
for discharge with mucus

→ It's more than a barrier
- Trapping various airborne virus, allergen or dirt particles
- Electrostatic effects work a priori with any charged particle

Drug free
Contains no active
pharmaceutical ingredient

⟶ It's a medical device
- No pharmacological, metabolic or immunologic activity
- Only physical effects

Preservative free
Safety by design including
special spray pump

→ It's well tolerated
- Commonly used preservatives tend to harm mucus membranes
- Commonly used preservatives may give unpleasant sensation

Protects for ≥ 3 hours
Gel designed for extended
nasal residence time

→ It's convenient
- Gel becomes liquid upon shaking, allowing to spray it
- Liquid turns into gel again when applied into nose

AM-301 Effectively Alleviates Allergy Symptoms

Primary efficacy endpoint met in clinical pollen challenge

Allergen challenge chamber

- Open-label randomized cross-over study
- 36 patients with allergic rhinitis to grass pollen
- Single dose of AM-301 spray or comparator prior to 4 hours of controlled pollen exposure
- Total Nasal Symptom Score (TNSS)
  - Nasal congestion, itching, sneezing, rhinorrhea
  - Preliminary analyses show non-inferiority of AM-301 to marketed comparator
- Rapid onset of protective effect
- Protection for at least 3 hours
- Well tolerated

AM-301 Decelerates SARS-CoV-2 Titer Growth

First *in vitro* data from application post infection



- Reconstituted human nasal epithelium model
  - Functional nasal mucosa
  - Without help from immune system or mucociliary clearance
  - Read-out through median Tissue Culture Infectious Dose, $TCID_{50}$, in Vero cells
- Daily treatment with AM-301 starting 24 or 30 hours post inoculation with SARS-CoV-2
  - Saline- and vehicle-treated and untreated controls
- Statistically significant deceleration of the viral titer growth compared to controls
  - p-value <0.01, linear mixed-effects model
- At Day 4 viral titers were 73.7-94.5% lower than controls

Introducing Bentrio™

Our brand name for marketing AM-301



Moving Towards Bentrio™ Commercialization

Launch planned in selected European countries in late Q2 2021

CE

Europe

- On track to meet essential requirements for marketing
- Roll-out in selected countries starting in June 2021
  - On- and offline distribution channels
- Expand market coverage rapidly during second half of 2021
- Collaborations with future licensing partners
- Significant, scalable contract manufacturing capacity

USA

- Intended use in allergy: 510(k) submission to FDA expected at around the time of CE mark conformity
- Intended use in viral infections: ongoing dialogue with Agency on applicable regulatory pathway

Market Potential for Bentrio™

Addressing frequent conditions

Allergies

- About 7.8% of people 18 and over in the US have hay fever Schiller et al., 2010
- 11.1 million visits to physician offices with primary diagnosis of allergic rhinitis National Ambulatory Medical Care Survey
- $4 billion market size for OTC allergy medicines in US in 2020 www.ibisworld.com

Viral infections

- Human rhinovirus (HRV) is most common cause of upper respiratory tract infection
- US revenues for could and cough remedies are expected > $12 billion in 2021 www.statista.com
- Influenza has resulted in 9-45 million illnesses, 140,000-810,000 hospitalizations and 12,000-61,000 deaths annually since 2010 Centers for Disease Control and Prevention
- Covid-19: 136.4 million cases and 2.94 million deaths to date


Auris Medical
Cochlear therapies


altamira
medica